Last reviewed · How we verify
NCT07153549: CTBE2502
Biolizin for Improving Functional Poor Appetite in Children Aged 6 to 36 Months (CTBE2502)
NA trial testing Biolizin in Feeding and Eating Disorders of Childhood in 110 participants. Currently enrolling.
25 April 2026
Quick facts
| Lead sponsor | Haiphong University of Medicine and Pharmacy |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 110 |
| Start date | 20 September 2025 |
| Primary completion | 25 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- Biolizin
- Standardized caregiver counseling on responsive feeding
Conditions studied
- Feeding and Eating Disorders of Childhood — all drugs for Feeding and Eating Disorders of Childhood →
- Appetite Disorders — all drugs for Appetite Disorders →
- Functional Poor Appetite — all drugs for Functional Poor Appetite →
Sponsor
Haiphong University of Medicine and Pharmacy
Who can join
Adults 6 Months to 36 Months, any sex, with Feeding and Eating Disorders of Childhood or Appetite Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Functional poor appetite is common in young children and may be linked to suboptimal micronutrient intake and feeding behavior. This study evaluates whether a zinc-containing oral supplement (Biolizin syrup) can improve eating behavior in children aged 6 to 36 months who have poor appetite without an identifiable medical cause. Participants are followed for 42 days with clinic visits at Day 0, Day 7, Day 21, and Day 42. Caregivers complete validated questionnaires about feeding difficulties and eating behavior; the child's weight and length/height are measured at each visit. Safety is assessed through review of adverse events and routine laboratory tests; serum zinc may be measured according to the protocol. The primary outcome is the change from baseline to Day 42 in the total score of a validated feeding-difficulty scale. Secondary outcomes include changes in Children's Eating Behaviour Questionnaire (CEBQ) subscales, WHO growth indices, serum zinc (if measured), and overall safety
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07153549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Haiphong University of Medicine and Pharmacy trials
Trials by the same sponsor.
- NCT07369622 — HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness · Phase 4 · not yet recruiting
- NCT07032558 — Comparison of DW-1021 and Separate Doses of Pelubi CR and Zytram CR Under Fasting Conditions · Phase 1 · recruiting
- NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
- NCT07148583 — BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months · NA · recruiting
- NCT06761339 — Clinical Trial Evaluate the Cough-relieving and Expectorant Effects of the Health Supplement AZKA Nasal and Throat for C · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07153549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haiphong University of Medicine and Pharmacy
- Last refreshed: 30 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07153549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing